Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Wednesday, Jul 19, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x